Need Help?

CRUK-ICGC Prostate Cancer Group Study

Prostate cancer somatic genomic sequencing data generated from 2011 onwards under auspices of the International Cancer Genome Consortium Prostate Cancer UK consortium (CRUK-ICGC Prostate Group), co-led by Colin Cooper and Ros Eeles, with other Principal Investigators (Brewer, Neal, Bova, McDermott, Wedge, Lynch, Massie, and Foster) and others as listed in study publications. Funded by Cancer Research UK and other funders as listed in study publications. Contents and publications related to each dataset are described with each dataset (EGAD) entry. Our study was funded with the ambition of collecting Whole Genome DNA sequence data from 250 prostate cancers, with matching transcriptome and methylome data. The original aims of the project were: 1.To understand the significance of multifocal prostate cancer. 2.To understand the clinical heterogeneity of prostate cancer to devise markers for predicting outcome and for drug targeting. 3.To understand the molecular basis of development and spread of castration-resistant and metastatic disease 4.To understand the aetiology of prostate cancer particularly the large variation in incidences that occur in different populations and ethnic groups. Please see for links between sample IDs reported in literature and EGA IDs.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000263 Illumina HiSeq 2000 18
EGAD00001000689 Illumina HiSeq 2000 -
EGAD00001000891 Illumina HiSeq 2000 62
EGAD00001000892 Illumina HiSeq 2000 40
EGAD00001001116 Illumina HiSeq 2000 150
EGAD00001002002 Illumina HiSeq 2000 20
EGAD00001003225 Illumina HiSeq 2000 221
EGAD00001004125 Illumina HiSeq 2000 71
EGAD00001010184 Illumina HiSeq 4000 376
EGAD00010000498 Affymetrix_SNP6- 18
Publications Citations
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
Nat Genet 47: 2015 367-372
Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.
Cold Spring Harb Mol Case Stud 2: 2016 a000752
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
PLoS Genet 13: 2017 e1007001
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Nat Genet 50: 2018 682-692
Inferring parsimonious migration histories for metastatic cancers.
Nat Genet 50: 2018 718-726
A Method for Identification of the Methylation Level of CpG Islands From NGS Data.
Sci Rep 10: 2020 8635
Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data.
Nat Commun 11: 2020 4301
Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy.
Nat Commun 11: 2020 5070
DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution.
Cell Syst 12: 2021 1004-1018.e10
Starfish infers signatures of complex genomic rearrangements across human cancers.
Nat Cancer 3: 2022 1247-1259
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Mol Cancer 21: 2022 183
Genomic evolution shapes prostate cancer disease type.
Cell Genom 4: 2024 100511
Evolving copy number gains promote tumor expansion and bolster mutational diversification.
Nat Commun 15: 2024 2025